ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Active Motif Incorporated Announces the Acquisition of Amaryllis Nucleics and their proprietary RNASeq workflow

CARLSBAD, Calif.: CARLSBAD, Calif., Jan. 27, 2022 /PRNewswire/ — Active Motif Incorporated, a company with the vision of bringing epigenetics more deeply into precision medicine, announced that it has purchased Amaryllis Nucleics, a Bay Area-based start-up company focused on proprietary RNA Sequencing methods. Amaryllis Nucleics provides Active Motif with a… Click here to view original post… […]

No Picture
News

Let There be Light

UC San Diego alumnus Lin Thu Hein has come full circle; after arriving in the United States from Myanmar at age 13, he is now using his degree in electrical engineering to bring solar-powered lighting to people … […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

How Protective are COVID Antibodies?

UC San Diego is conducting what is believed to be the largest research study yet of SARS-CoV-2 antibodies and the protection they impart against contracting COVID-19. The ZAP COVID-19 is a two-year study designe… […]

No Picture
News

New Drug Screening Method Answers Why Alzheimer’s Drugs Fail, Suggests New Targets

A study led by UC San Diego sheds light on why Alzheimer’s drugs so far have been ineffective at curing or reversing the disease. The researchers identify new targets for drug development and present a new method to screen drugs for treating Alzheimer’s disease. Click here to view original post… […]

No Picture
News

AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022

CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $AVRO–AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

SAN DIEGO, Calif. and CALGARY, AB: Enrollment in the first dose escalation is complete with no safety issues reported to date Trial is designed to accelerate pelareorep’s development in Asian territories such as China, the world’s second-largest pharmaceutical market SAN DIEGO, Calif. and CALGARY, AB, Jan. 27, 2022 /PRNewswire/ –… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks
No Picture
Uncategorized

Senior Director Financial Planning and Analysis – Acadia Pharmaceuticals Inc. – San Diego, CA

Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical…From ACADIA Pharmaceuticals Inc. – Wed, 26 Jan 2022 19:11:31 GMT – View all San Diego, […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Rick Hancock named as Board Chairman for BioCina

SAN DIEGO and ADELAIDE, Australia: SAN DIEGO and ADELAIDE, Australia, Jan. 26, 2022 /PRNewswire/ — BioCina, a leading contract development and manufacturing organization (CDMO) announces the appointment of Rick Hancock, Chairman of the Board. Hancock, with over 35 years of experience in life sciences, has held various board, executive and… Click here to view original post… […]

No Picture
News

Salk Professor Samuel Pfaff named 2021 AAAS Fellow

LA JOLLA—Salk Professor Samuel Pfaff has been named a 2021 Fellow of the American Association for the Advancement of Science (AAAS), the world’s largest general scientific society and publisher of the journal Science. Pfaff is among 564 new AAAS Fellows spanning 24 scientific disciplines who were nominated by their… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

BioTheryX Doses First Patient in Phase 1 Study Investigating Lead Protein Degrader Candidate BTX-1188

SAN DIEGO: SAN DIEGO, Jan. 26, 2022 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on developing targeted protein degraders to create life-saving medicines, today announced dosing of the first patient in a new, first-in human Phase 1 study investigating its lead candidate BTX-1188, an oral, dual target protein degrader… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
Uncategorized

Senior Manager, Market Development – Biotech, North America – Thermo Fisher Scientific – San Diego, CA

The Senior Manager, Market Development, Biotech for the Biosciences Division is a member of the North America Market Development team, responsible for the…From Thermo Fisher Scientific – Wed, 26 Jan 2022 08:26:20 GMT – View […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Zef Scientific and Evosep Partner to Increase and Improve US Service Coverage

SAN DIEGO: SAN DIEGO, Jan. 25, 2022 /PRNewswire/ — Today, Zef Scientific, Inc. and Evosep, announce that they have entered a partnership to increase and improve the US service coverage for the growing Evosep One install base. The agreement covers all service aspects from installations over warranty provision, preventive maintenance,… Click here to view original post… […]